Cow's Milk Allergy: Can Immunotherapy Be the Answer?
"A comprehensive look at immunotherapy for cow's milk allergy, exploring its effectiveness, safety, and future directions."
Cow's milk allergy (CMA) is a common food hypersensitivity, particularly among young children. While many children outgrow it, some experience persistent allergic reactions, impacting their diet and quality of life. Traditional management focuses on allergen avoidance, but emerging strategies like immunotherapy offer the potential for clinical tolerance.
Oral immunotherapy (OIT) has emerged as a promising approach to managing CMA. OIT involves gradually introducing small amounts of cow's milk protein to desensitize the allergic individual. This method has shown effectiveness in several studies, although it's not without its challenges, including adverse events and the lack of standardized protocols.
This article explores the current landscape of immunotherapy for CMA, examining its efficacy, safety considerations, and future directions. We'll delve into different immunotherapy approaches, including oral, sublingual, and epicutaneous methods, as well as innovative strategies like microwave-heated milk and combination therapies.
How Common Is Cow’s Milk Allergy?
Cow’s milk allergy is one of the most common food allergies in children, and its population-level burden among adults and older children in the United States remains less clear. Oral immunotherapy (OIT) is used for young children with cow’s milk allergy and has shown efficacy in several studies, but adverse events occur frequently. A 2017 review also noted that only five randomized trials were available at that time. Long-term follow-up evidence has been described as scarce, including for children with severe IgE-mediated allergy treated with OIT.
Changing Views of Natural History
A 2013 review described cow’s milk allergy as the most common food allergy in children, with estimated rates of 2% to 3%. It recounted a 2007 speculation by Johns Hopkins investigators that food allergies might be resolving less often and taking longer to resolve. The review situated this question within work by the National Institutes of Health–sponsored Consortium on Food Allergy Research. A later study defined tolerance as passing an oral challenge with 200 mL of unheated cow’s milk or consuming that amount without symptoms, and persistent allergy as not meeting either criterion by age 12; children receiving OIT were excluded from its primary analysis.
Oral Immunotherapy: How it Works
Oral immunotherapy (OIT) involves a structured process of gradually increasing the amount of cow's milk protein a person with CMA consumes. The goal is to desensitize the immune system, reducing its reaction to the allergen over time. A typical OIT protocol consists of three phases:
- Escalation phase: Conducted under strict medical supervision, this phase involves introducing tiny amounts of cow's milk protein and gradually increasing the dose every 30 minutes to 2 hours until a tolerated dose is reached.
- Build-up phase: This phase continues at home, with the daily dose gradually increased weekly or biweekly until a target dose (typically around 200ml of cow's milk) is reached.
- Maintenance phase: Once the target dose is achieved, it's continued daily for months or years to maintain desensitization. Some protocols include a double-blind placebo-controlled food challenge (DBPCFC) after a period of maintenance to assess tolerance.
Immune Mechanisms and Experimental Treatment
A review of early and emerging approaches to managing IgE-mediated cow’s milk protein allergy describes IgG4 as competing with allergen-specific antibodies for allergen binding and inhibiting basophil and mast-cell activation. Separately, a mouse-model study investigated DL-propargylglycine, reporting that its administration inhibited TET2 and FOXP3 expression and alleviated symptoms of neonatal cow’s milk allergy. The study’s background notes that oral immunotherapy is regularly used for cow’s milk allergy and has shown efficacy in previous studies. The mouse-model finding is preclinical and does not establish that DL-propargylglycine treats human allergy.
OIT’s Unresolved Risks and Reintroduction Questions
A review identifies unresolved problems with cow’s milk OIT and suggests that combining it with omalizumab and less allergenic heated milk products may help address them; this is presented as a possibility, not an established solution. In one report, only 25% of patients showed adequate immediate and late oral tolerance alongside negative immunological test results for adverse reactions, with findings indicating cross-reactivity between proteins in vivo and in vitro. Reintroducing cow’s milk remains a clinical dilemma because it is essential in infancy and necessary for adequate growth. A 2019 study specifically examined side effects of cow’s milk OIT using consensus definitions of food-induced anaphylaxis.
Maintenance Doses and Milk Alternatives
A 2025 retrospective study compared three-year safety and efficacy for high- and low-dose OIT in people with anaphylactic cow’s milk allergy; its source summary notes that long-term evidence on maintenance doses is insufficient. A separate review compares the nutritional content of cow’s milk with common alternatives available in Canada and summarizes recommendations for alternatives for children with cow’s milk allergy. The World Allergy Organization states that cow’s milk allergy is usually outgrown by age 5, though it persists beyond early childhood in some individuals, and describes OIT as a proposed strategy for persistent IgE-mediated allergy. These sources address different comparisons, so they do not establish that one OIT dose or milk alternative is best overall.
The Future of Immunotherapy for Cow's Milk Allergy
Immunotherapy for CMA is an evolving field with promising potential. Studies have shown that CM-OIT can lead to desensitization in many individuals with IgE-related CMA, though long-term tolerance needs more study.
Efficacy With Important Caveats
A meta-analysis reports that OIT is effective for children with IgE-mediated cow’s milk allergy, especially those older than 3 years, while also noting that OIT can cause adverse effects that are mostly mild to moderate. The same source material emphasizes that adverse events occur frequently during OIT and that only five randomized trials were available in the reviewed evidence. It also highlights the unresolved question of when to reintroduce cow’s milk, an essential food in infancy. Taken together, the findings support potential benefit while underscoring limits in the evidence and practical questions about treatment.
Personalized and Baked-Milk Approaches
A 2026 article reports that OIT desensitizes most children with cow’s milk allergy, while sustained unresponsiveness varies with the protocol used. It also reports that anti-IgE biologic agents improve tolerability and may expand eligibility for high-risk patients. In a separate 2024 news summary, baked-milk OIT research is described as providing evidence for potential future treatment paths, with oropharyngeal and gastrointestinal symptoms reported as the most common. These sources point to approaches under investigation rather than establishing a single settled treatment pathway.
Machine-Learning-Based Immunotherapy
A 2024 report describes the Tolerance Induction Program (TIP), an immunotherapy that applies machine learning contextualized on immunologic and food-protein datasets. The report says TIP has established efficacy toward peanut allergy and demonstrates equal efficacy toward cow’s milk anaphylaxis. It defines maintained remission outcomes as at least 7 days of unresponsiveness to high-dose protein exposures. These claims are reported for this specific program and do not by themselves establish broader effectiveness across patients or treatment settings.
New approaches, like combining OIT with omalizumab (an anti-IgE antibody) or using microwave-heated milk, are being explored to improve safety and effectiveness. These strategies aim to reduce the risk of allergic reactions and enhance tolerance.
While immunotherapy offers hope for managing CMA, it's crucial to consult with an allergist or qualified healthcare professional to determine the best course of treatment. Further research and standardized protocols will be crucial to optimizing the safety and efficacy of immunotherapy for CMA.